Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma

Imre Rényi, Edit Bárdi, Erzsébet Udvardi, Gábor Kovács, Katalin Bartyik, Pál Kajtár, Péter Masát, K. Nagy, Ilona Galántai, C. Kiss

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

To prevent acute renal failure in children at risk for developing tumor lysis syndrome due to acute lymphoblastic leukemia or non-Hodgkin's lymphoma treated according to international BFM protocols, we investigated recombinant urate oxidase (rasburicase) in the first Central European open-labeled, prospective, multicenter phase IV trial. Rasburicase was administered intravenously, at 0.2 mg/kg for 5 consecutive days to 36 patients. Blood levels of uric acid, creatinine, phosphorus, calcium, lactate dehydrogenase and complete blood count were measured daily during rasburicase treatment and on days 6, 7 and 12. Initial uric acid level decreased significantly by 4 hours (from 343 μmol/L to 58 μmol/L, p

Original languageEnglish
Pages (from-to)57-62
Number of pages6
JournalPathology and Oncology Research
Volume13
Issue number1
Publication statusPublished - Mar 31 2007

Fingerprint

Hyperuricemia
Non-Hodgkin's Lymphoma
Leukemia
Uric Acid
Tumor Lysis Syndrome
Urate Oxidase
Blood Cell Count
Precursor Cell Lymphoblastic Leukemia-Lymphoma
L-Lactate Dehydrogenase
Acute Kidney Injury
Phosphorus
Creatinine
Therapeutics
Calcium
rasburicase

Keywords

  • Leukemia
  • Lymphoma
  • Rasburicase
  • Tumor lysis syndrome
  • Uric acid

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma. / Rényi, Imre; Bárdi, Edit; Udvardi, Erzsébet; Kovács, Gábor; Bartyik, Katalin; Kajtár, Pál; Masát, Péter; Nagy, K.; Galántai, Ilona; Kiss, C.

In: Pathology and Oncology Research, Vol. 13, No. 1, 31.03.2007, p. 57-62.

Research output: Contribution to journalArticle

Rényi, I, Bárdi, E, Udvardi, E, Kovács, G, Bartyik, K, Kajtár, P, Masát, P, Nagy, K, Galántai, I & Kiss, C 2007, 'Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma', Pathology and Oncology Research, vol. 13, no. 1, pp. 57-62.
Rényi I, Bárdi E, Udvardi E, Kovács G, Bartyik K, Kajtár P et al. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma. Pathology and Oncology Research. 2007 Mar 31;13(1):57-62.
Rényi, Imre ; Bárdi, Edit ; Udvardi, Erzsébet ; Kovács, Gábor ; Bartyik, Katalin ; Kajtár, Pál ; Masát, Péter ; Nagy, K. ; Galántai, Ilona ; Kiss, C. / Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma. In: Pathology and Oncology Research. 2007 ; Vol. 13, No. 1. pp. 57-62.
@article{bab710f186764748b94dce82d0d2840a,
title = "Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma",
abstract = "To prevent acute renal failure in children at risk for developing tumor lysis syndrome due to acute lymphoblastic leukemia or non-Hodgkin's lymphoma treated according to international BFM protocols, we investigated recombinant urate oxidase (rasburicase) in the first Central European open-labeled, prospective, multicenter phase IV trial. Rasburicase was administered intravenously, at 0.2 mg/kg for 5 consecutive days to 36 patients. Blood levels of uric acid, creatinine, phosphorus, calcium, lactate dehydrogenase and complete blood count were measured daily during rasburicase treatment and on days 6, 7 and 12. Initial uric acid level decreased significantly by 4 hours (from 343 μmol/L to 58 μmol/L, p",
keywords = "Leukemia, Lymphoma, Rasburicase, Tumor lysis syndrome, Uric acid",
author = "Imre R{\'e}nyi and Edit B{\'a}rdi and Erzs{\'e}bet Udvardi and G{\'a}bor Kov{\'a}cs and Katalin Bartyik and P{\'a}l Kajt{\'a}r and P{\'e}ter Mas{\'a}t and K. Nagy and Ilona Gal{\'a}ntai and C. Kiss",
year = "2007",
month = "3",
day = "31",
language = "English",
volume = "13",
pages = "57--62",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma

AU - Rényi, Imre

AU - Bárdi, Edit

AU - Udvardi, Erzsébet

AU - Kovács, Gábor

AU - Bartyik, Katalin

AU - Kajtár, Pál

AU - Masát, Péter

AU - Nagy, K.

AU - Galántai, Ilona

AU - Kiss, C.

PY - 2007/3/31

Y1 - 2007/3/31

N2 - To prevent acute renal failure in children at risk for developing tumor lysis syndrome due to acute lymphoblastic leukemia or non-Hodgkin's lymphoma treated according to international BFM protocols, we investigated recombinant urate oxidase (rasburicase) in the first Central European open-labeled, prospective, multicenter phase IV trial. Rasburicase was administered intravenously, at 0.2 mg/kg for 5 consecutive days to 36 patients. Blood levels of uric acid, creatinine, phosphorus, calcium, lactate dehydrogenase and complete blood count were measured daily during rasburicase treatment and on days 6, 7 and 12. Initial uric acid level decreased significantly by 4 hours (from 343 μmol/L to 58 μmol/L, p

AB - To prevent acute renal failure in children at risk for developing tumor lysis syndrome due to acute lymphoblastic leukemia or non-Hodgkin's lymphoma treated according to international BFM protocols, we investigated recombinant urate oxidase (rasburicase) in the first Central European open-labeled, prospective, multicenter phase IV trial. Rasburicase was administered intravenously, at 0.2 mg/kg for 5 consecutive days to 36 patients. Blood levels of uric acid, creatinine, phosphorus, calcium, lactate dehydrogenase and complete blood count were measured daily during rasburicase treatment and on days 6, 7 and 12. Initial uric acid level decreased significantly by 4 hours (from 343 μmol/L to 58 μmol/L, p

KW - Leukemia

KW - Lymphoma

KW - Rasburicase

KW - Tumor lysis syndrome

KW - Uric acid

UR - http://www.scopus.com/inward/record.url?scp=34250000800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250000800&partnerID=8YFLogxK

M3 - Article

C2 - 17387390

AN - SCOPUS:34250000800

VL - 13

SP - 57

EP - 62

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 1

ER -